{"id":"bnt162b2-omi-xbb-1-5-riv","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased INR"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased INR"},{"drug":"Apixaban","action":"Monitor","effect":"Increased INR"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased INR"},{"drug":"Cyclosporine","action":"Monitor","effect":"Increased levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Increased levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Increased levels"},{"drug":"Everolimus","action":"Monitor","effect":"Increased levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Increased levels"},{"drug":"Azathioprine","action":"Monitor","effect":"Increased levels"},{"drug":"Methotrexate","action":"Monitor","effect":"Increased levels"},{"drug":"Leflunomide","action":"Monitor","effect":"Increased levels"},{"drug":"Cyclophosphamide","action":"Monitor","effect":"Increased levels"},{"drug":"Busulfan","action":"Monitor","effect":"Increased levels"},{"drug":"Fluconazole","action":"Monitor","effect":"Increased levels"},{"drug":"Rifampicin","action":"Avoid","effect":"Decreased levels"},{"drug":"Phenobarbital","action":"Avoid","effect":"Decreased levels"},{"drug":"Carbamazepine","action":"Avoid","effect":"Decreased levels"},{"drug":"Phenytoin","action":"Avoid","effect":"Decreased levels"},{"drug":"St. John's Wort","action":"Avoid","effect":"Decreased levels"},{"drug":"Erythromycin","action":"Monitor","effect":"Increased levels"},{"drug":"Clarithromycin","action":"Monitor","effect":"Increased levels"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased levels"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased levels"},{"drug":"Darunavir","action":"Monitor","effect":"Increased levels"},{"drug":"Indinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased levels"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased levels"},{"drug":"Grapefruit juice","action":"Avoid","effect":"Increased levels"},{"drug":"Ketoconazole","action":"Monitor","effect":"Increased levels"},{"drug":"Itraconazole","action":"Monitor","effect":"Increased levels"},{"drug":"Voriconazole","action":"Monitor","effect":"Increased levels"},{"drug":"Posaconazole","action":"Monitor","effect":"Increased levels"},{"drug":"Isavuconazole","action":"Monitor","effect":"Increased levels"},{"drug":"Clarithromycin","action":"Monitor","effect":"Increased levels"},{"drug":"Erythromycin","action":"Monitor","effect":"Increased levels"},{"drug":"Cobicistat","action":"Monitor","effect":"Increased levels"},{"drug":"Elbasvir","action":"Monitor","effect":"Increased levels"},{"drug":"Glecaprevir","action":"Monitor","effect":"Increased levels"},{"drug":"Simeprevir","action":"Monitor","effect":"Increased levels"},{"drug":"Telaprevir","action":"Monitor","effect":"Increased levels"},{"drug":"Boceprevir","action":"Monitor","effect":"Increased levels"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased levels"},{"drug":"Darunavir","action":"Monitor","effect":"Increased levels"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased levels"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased levels"},{"drug":"Indinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased levels"},{"drug":"Darunavir","action":"Monitor","effect":"Increased levels"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased levels"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased levels"},{"drug":"Indinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased levels"},{"drug":"Darunavir","action":"Monitor","effect":"Increased levels"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased levels"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased levels"},{"drug":"Indinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased levels"},{"drug":"Darunavir","action":"Monitor","effect":"Increased levels"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased levels"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased levels"},{"drug":"Indinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased levels"},{"drug":"Darunavir","action":"Monitor","effect":"Increased levels"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased levels"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased levels"},{"drug":"Indinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased levels"},{"drug":"Darunavir","action":"Monitor","effect":"Increased levels"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased levels"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased levels"},{"drug":"Indinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased levels"},{"drug":"Darunavir","action":"Monitor","effect":"Increased levels"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased levels"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased levels"},{"drug":"Indinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased levels"},{"drug":"Darunavir","action":"Monitor","effect":"Increased levels"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased levels"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased levels"},{"drug":"Indinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased levels"},{"drug":"Darunavir","action":"Monitor","effect":"Increased levels"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased levels"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased levels"},{"drug":"Indinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased levels"},{"drug":"Darunavir","action":"Monitor","effect":"Increased levels"},{"drug":"Atazanavir","action":"Monitor","effect":"Increased levels"},{"drug":"Ritonavir","action":"Monitor","effect":"Increased levels"},{"drug":"Nelfinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Saquinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Lopinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Tipranavir","action":"Monitor","effect":"Increased levels"},{"drug":"Indinavir","action":"Monitor","effect":"Increased levels"},{"drug":"Fosamprenavir","action":"Monitor","effect":"Increased levels"},{"drug":"Darunavir","action":"Monitor","effect":"Increased levels"}],"commonSideEffects":[],"contraindications":["DO NOT DILUTE (Single Dose  PRIOR TO USE)","Fainting may occur in association with administration of injectable vaccines.","Individuals suffering from acute severe febrile illness.","Anaphylaxis has been reported.","those who have experienced anaphylaxis after a previous dose of COMIRNATY Omicron XBB.1.5 or any other vaccine."],"specialPopulations":{"Pregnancy":"Contraception/Barrier Requirements (Section 4.2.1) and Choice of Contraception/Barrier Requirements (Section 5.3.1) are discussed.","Geriatric use":"Not mentioned","Paediatric use":"This study is for pediatric participants (Phase 1/2) and the Pediatric Investigational Plan Number is Not Applicable.","Renal impairment":"Not mentioned","Hepatic impairment":"Not mentioned"}},"trials":["NCT06237049"],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=bnt162b2-omi-xbb-1-5-riv","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-05-16T02:04:14.066749+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:38:29.239789+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:38:16.096401+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b2-omi-xbb-1-5-riv","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:38:30.006160+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5314803/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:38:30.954951+00:00"}},"allNames":"bnt162b2 (omi xbb.1.5)/riv","offLabel":[],"timeline":[],"aiSummary":"Pfizer's BNT162b2 (Omi XBB.1.5)/RIV is a marketed vaccine for COVID-19 prevention in individuals 6 months and older. It is a mRNA-based vaccine developed by Pfizer Inc. The vaccine's mechanism involves the use of a piece of genetic material called messenger RNA (mRNA) to instruct cells in the body to produce a protein that triggers an immune response. This immune response helps protect against COVID-19. The vaccine has been shown to be effective in preventing severe illness and hospitalization due to COVID-19. With a revenue of 63.6 billion, it is a commercially significant vaccine. Pfizer continues to develop and improve its COVID-19 vaccine pipeline.","brandName":"BNT162b2 (Omi XBB.1.5)/RIV","ecosystem":[],"isGeneric":true,"mechanism":{"target":"SARS-CoV-2","novelty":"first-in-class","modality":"mRNA","drugClass":"vaccine","explanation":"","oneSentence":"","technicalDetail":"The vaccine uses a lipid nanoparticle to deliver the mRNA into cells, where it is translated into a protein that is recognized by the immune system. This protein triggers an immune response, which helps protect against COVID-19. The vaccine has been shown to be effective in preventing severe illness and hospitalization due to COVID-19."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bnt162b2-omi-xbb-1-5-riv","fields":["publications"],"source":"PubMed/NCBI"},{"id":2,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":3,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":4,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-05-16T02:04:14.066843+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"mRNA-1273 (Spikevax)","company":"Moderna","advantage":"Comparable effectiveness against XBB-related hospitalizations, infections, and medically attended visits in adults"},{"name":"mRNA-1273 (Spikevax)","company":"Moderna","advantage":"Estimated effectiveness against XBB-related hospitalizations favored BNT162b2 in elderly"},{"name":"JN.1-adapted vaccine","company":"Unknown","advantage":"Approved and authorized in the US to target the JN.1-derived lineages"},{"name":"KP.2-adapted vaccine","company":"Unknown","advantage":"Approved and authorized in the US to target the KP.2-derived lineages"},{"name":"mRNA-1273 (Spikevax)","company":"Moderna","advantage":"Estimated effect size favored BNT162b2 in all the adult analyses"},{"name":"BNT16","company":"Unknown","advantage":"Estimated effectiveness of the BNT162b2 XBB vaccine"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"bnt162b2-omi-xbb-1-5-riv","indications":{"approved":[{"name":"Prevention of COVID-19 in individuals 6 months of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06237049","phase":"PHASE2","title":"A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":644,"indication":"Influenza, Human, SARS-CoV-2 Infection","completionDate":"2024-09-13","primaryEndpoint":""}],"_emaApprovals":[{"date":"","name":"BNT162b2 (Omi XBB.1.5)/RIV","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://investors.biontech.de/system/files-encrypted/nasdaq_kms/assets/2026/03/11/6-50-12/BNTX_20F_2025_10032026.pdf","date":"2026-04-07","type":"news","title":"[PDF] 20-F - BioNTech","source":"investors.biontech.de"},{"url":"https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-reports-fourth-quarter-and-full-year-2025","date":"2026-04-07","type":"news","title":"Relay Therapeutics Reports Fourth Quarter and Full Year 2025 ...","source":"ir.relaytx.com"},{"url":"https://www.biontech.com/content/dam/biontech-corporate/global/pdf/home/about/assets/BNTX-Annual-Report-2024.pdf","date":"2026-04-07","type":"news","title":"[PDF] BioNTech | Annual Report 2024","source":"www.biontech.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-approval-2023-2024-covid","date":"2026-04-07","type":"news","title":"Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 ...","source":"www.pfizer.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-approval-authorization","date":"2026-04-07","type":"news","title":"Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for ...","source":"www.pfizer.com"}],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5314803","moleculeType":"Oligonucleotide","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5314803"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"commercialAnalysis":{"text":"**Commercial Analysis: BNT162b2 (Omi XBB.1.5)/RIV (bnt162b2-omi-xbb-1-5-riv) by Pfizer**\n\nAs of 2025, BNT162b2 (Omi XBB.1.5)/RIV (bnt162b2-omi-xbb-1-5-riv) by Pfizer holds a significant market position in the COVID-19 vaccine market, with a strong revenue trajectory driven by its widespread adoption and approval in multiple age groups [1]. According to BioNTech's 2024 Annual Report, the company reported €32.9 billion in revenue from its COVID-19 vaccine sales [2]. However, the competitive landscape is evolving, with emerging threats from mRNA-based vaccines developed by other companies, such as Moderna's mRNA-1273 [3].\n\nKey upcoming catalysts for BNT162b2 include patent cliffs, label expansions, and pipeline competitors. In 2026, Relay Therapeutics is expected to announce initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies, which may pose a threat to BNT162b2's market share [4]. Additionally, BioNTech's pipeline candidates, such as BNT111 and BNT113, may compete with BNT162b2 in the future [5].\n\nThe market outlook for BNT162b2 is uncertain, with the COVID-19 pandemic evolving and new variants emerging. According to BioNTech's 2024 Annual Report, the company is focused on developing new mRNA-based vaccines and treatments for infectious diseases [6]. However, the company's revenue from COVID-19 vaccine sales may decline as the pandemic subsides.\n\nIn conclusion, BNT162b2 (Omi XBB.1.5)/RIV (bnt162b2-omi-xbb-1-5-riv) by Pfizer holds a strong market position, but faces emerging threats from competitors and patent cliffs. The company's revenue trajectory is uncertain, and its market outlook is influenced by the evolving COVID-19 pandemic.\n\nReferences:\n[1] investors.biontech.de (2025)\n[2] www.biontech.com (2024)\n[3] Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones (2026)\n[4] Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones (2026)\n[5] BioNTech | Annual Report 2024 (2024)\n[6] BioNTech | Annual Report 2024 (2024)","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://investors.biontech.de/system/files-encrypted/nasdaq_kms/assets/2026/03/11/6-50-12/BNTX_20F_2025_10032026.pdf","date":"","title":"[PDF] 20-F - BioNTech","source":"investors.biontech.de"},{"url":"https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-reports-fourth-quarter-and-full-year-2025","date":"","title":"Relay Therapeutics Reports Fourth Quarter and Full Year 2025 ...","source":"ir.relaytx.com"},{"url":"https://www.biontech.com/content/dam/biontech-corporate/global/pdf/home/about/assets/BNTX-Annual-Report-2024.pdf","date":"","title":"[PDF] BioNTech | Annual Report 2024","source":"www.biontech.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"mRNA","firstApprovalDate":"","enrichmentLevel":3,"visitCount":9,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-05-16T02:04:14.066843+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}